Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...

What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...

When is the next Monster Hunter Wilds beta? The previous Monster Hunter Wilds open beta included a limited portion of the game for players to test, including spending time in the character creator ...

PAUL HUNTER was an iconic snooker player when he was alive and his legacy has continued long after his death aged just 27. Every year at the Masters tournament the sportsman is remembered ...

Kick It Out (KIO) has asked Fifa if it has taken any action over a video posted on social media by Chelsea's Enzo Fernandez last year featuring an alleged "racist and transphobic" chant.

Fifteen-year-old Dominic Henriquez from Prosper, Texas, is bringing hope to boys like him who live with Hunter syndrome, a rare genetic disorder that primarily affects males. Dominic’s journey ...

Nip­pon Shinyaku has paid $110 mil­lion up­front for the rights to sell two of Re­genxbio’s gene ther­a­pies for mu­copolysac­cha­ri­do­sis in the US and Asia. … ...

RegenxBio said Tuesday that Kyoto, Japan’s Nippon Shinyaku Co. Ltd. will develop and commercialize its one-time gene therapies for Hunter syndrome and Hurler syndrome, both affecting children.

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.

Prosecutors had been investigating the president's son since 2018. A month before leaving office, President Joe Biden announced that he has issued a pardon for his son Hunter Biden, who was ...

The partnership will focus on advancing RGX-121 as a treatment for mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for treating mucopolysaccharidosis I (MPS I), also ...